Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotine Sublingual Tablets for Smoking Cessation in COPD
NCT00132236Phase 3Terminated
- Sponsor
- Gentofte Hospital
- Start
- Feb 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nicotine in nicotine dependence (4 arms), sponsored by Gentofte Hospital. Primary endpoint: Smoking cessation at 12 months. Started Feb 2002; status: terminated.
02
Drugs
nicotine
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00132236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132236.